Procter & Gamble Health Limited - Asset Resilience Ratio
Procter & Gamble Health Limited (PGHL) has an Asset Resilience Ratio of 33.01% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check PGHL capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2024)
This chart shows how Procter & Gamble Health Limited's Asset Resilience Ratio has changed over time. See net asset quality index of Procter & Gamble Health Limited to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Procter & Gamble Health Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Procter & Gamble Health Limited stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs2.79 Billion | 31.23% |
| Short-term Investments | Rs159.40 Million | 1.78% |
| Total Liquid Assets | Rs2.95 Billion | 33.01% |
Asset Resilience Insights
- Very High Liquidity: Procter & Gamble Health Limited maintains exceptional liquid asset reserves at 33.01% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Procter & Gamble Health Limited Industry Peers by Asset Resilience Ratio
Compare Procter & Gamble Health Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Procter & Gamble Health Limited (2003–2024)
The table below shows the annual Asset Resilience Ratio data for Procter & Gamble Health Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 14.33% | Rs1.14 Billion ≈ $12.31 Million |
Rs7.94 Billion ≈ $85.89 Million |
-6.95pp |
| 2023-12-31 | 21.27% | Rs1.69 Billion ≈ $18.28 Million |
Rs7.94 Billion ≈ $85.91 Million |
-11.18pp |
| 2022-12-31 | 32.45% | Rs3.57 Billion ≈ $38.65 Million |
Rs11.01 Billion ≈ $119.09 Million |
-5.27pp |
| 2021-12-31 | 37.72% | Rs3.37 Billion ≈ $36.46 Million |
Rs8.94 Billion ≈ $96.65 Million |
-5.76pp |
| 2020-12-31 | 43.48% | Rs4.29 Billion ≈ $46.37 Million |
Rs9.86 Billion ≈ $106.65 Million |
-7.40pp |
| 2019-12-31 | 50.88% | Rs5.99 Billion ≈ $64.73 Million |
Rs11.76 Billion ≈ $127.22 Million |
+18.21pp |
| 2018-12-31 | 32.67% | Rs5.75 Billion ≈ $62.17 Million |
Rs17.59 Billion ≈ $190.28 Million |
+25.61pp |
| 2017-12-31 | 7.06% | Rs699.70 Million ≈ $7.57 Million |
Rs9.91 Billion ≈ $107.20 Million |
+3.91pp |
| 2016-12-31 | 3.15% | Rs277.80 Million ≈ $3.00 Million |
Rs8.83 Billion ≈ $95.47 Million |
-2.25pp |
| 2015-12-31 | 5.39% | Rs422.80 Million ≈ $4.57 Million |
Rs7.84 Billion ≈ $84.78 Million |
+2.02pp |
| 2014-12-31 | 3.37% | Rs238.70 Million ≈ $2.58 Million |
Rs7.08 Billion ≈ $76.59 Million |
-0.37pp |
| 2013-12-31 | 3.74% | Rs242.90 Million ≈ $2.63 Million |
Rs6.49 Billion ≈ $70.14 Million |
-0.23pp |
| 2012-12-31 | 3.98% | Rs236.40 Million ≈ $2.56 Million |
Rs5.94 Billion ≈ $64.27 Million |
-17.82pp |
| 2006-12-31 | 21.80% | Rs1.04 Billion ≈ $11.30 Million |
Rs4.79 Billion ≈ $51.84 Million |
+0.55pp |
| 2005-12-31 | 21.25% | Rs823.10 Million ≈ $8.90 Million |
Rs3.87 Billion ≈ $41.90 Million |
+7.70pp |
| 2004-12-31 | 13.54% | Rs442.80 Million ≈ $4.79 Million |
Rs3.27 Billion ≈ $35.36 Million |
+2.75pp |
| 2003-12-31 | 10.79% | Rs300.00 Million ≈ $3.24 Million |
Rs2.78 Billion ≈ $30.07 Million |
-- |
About Procter & Gamble Health Limited
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter … Read more